Qualigen Therapeutics, Inc. (NASDAQ:QLGN – Get Free Report) shares fell 3.3% during mid-day trading on Wednesday. The company traded as low as $1.45 and last traded at $1.45. 343,495 shares were traded during mid-day trading, a decline of 77% from the average session volume of 1,521,488 shares. The stock had previously closed at $1.50.
Qualigen Therapeutics Stock Performance
The company has a market capitalization of $2.46 million, a P/E ratio of -0.19 and a beta of 0.24. The firm’s fifty day moving average is $1.08 and its 200 day moving average is $1.16.
Qualigen Therapeutics Company Profile
Qualigen Therapeutics, Inc is a clinical-stage biotechnology company focused primarily on developing therapies for cancer and other serious diseases. The company’s lead therapeutic program is QN-302, a small-molecule drug candidate being investigated for its potential to treat solid tumors, including pancreatic cancer.
Qualigen is also developing additional oncology-focused programs, including QN-247, an aptamer-based candidate designed to target nucleolin, a protein associated with cancer-cell growth and survival.
Read More
- Five stocks we like better than Qualigen Therapeutics
- Tesla Wants to Make Its Own Chips—What Could Go Wrong?
- IREN Limited’s AI Pivot Gains Traction—But Can Its Data Centers Deliver?
- PBF Energy’s Stunning Rally Faces a Critical Test
- Citi Stock Falls Despite Earnings Beat: What Investors Need to Know
Receive News & Ratings for Qualigen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qualigen Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
